Dr Stuart CollinsonChairman and CEO
Dr Collinson’s career includes executive leadership and board roles with public and private life science companies in the US and Europe, and as a partner with a venture capital firm.
He has served on the boards of companies including Affinium Pharmaceuticals (acquired by Debiopharm), Cabrellis Pharmaceuticals (acquired by Pharmion, now part of Celgene), Conforma Therapeutics (acquired by Biogen), Essentialis (acquired by Capnia, now Soleno Therapeutics), GeneOhm Sciences (acquired by Becton Dickinson), NovaCardia (acquired by Merck & Co), and Vertex Pharmaceuticals.
As a life science partner with Forward Ventures, Dr Collinson has led investments in numerous biopharmaceutical companies. Previously, he was Chairman and CEO of Aurora Biosciences (acquired by Vertex Pharmaceuticals). He held senior management positions at GlaxoWellcome (now GlaxoSmithKline) and Baxter International, and was a consultant with The Boston Consulting Group.
Dr Collinson received an MBA from Harvard Business School (Fulbright Scholar), a DPhil (PhD) in Physical Chemistry from the University of Oxford.
Raymond SpencerChief Financial Officer
Raymond Spencer, CFO has over 30 years’ experience as a senior financial officer in biotech. For 12 years he was the CFO of LSE listed Antisoma plc. Whilst at Antisoma he was instrumental in completing the IPO in 1998, several fund-raising rounds that totalled over £100 million, the acquisition of two private US biotech companies and the closing of three licensing deals with big pharma with total upfront licence fees exceeding £100m.
Raymond was CFO for AIM listed Summit plc for 5 years to July 2014 having completed a restructuring of the company, raised over £20m in equity financing and the acquisition of the Oxford University spin-out MuOx Ltd. Raymond is currently part-time founder, Director and CFO of MGB-Biopharma Ltd, which has raised over £6m from angel investors, Scottish Enterprise and won a Biomedical Catalyst award from Innovate UK to progress drugs for treatment of anti-microbial resistance. He has also established his own consultancy company, Bio-CFO Ltd providing services to biotech and cleantech companies. Raymond qualified as a chartered accountant with KPMG in 1979.
Professor Steve DaviesWaynflete Professor of Chemistry
Professor Steve Davies obtained his BA in 1973 from the University of Oxford and his D.Phil. in 1975. He subsequently held an ICI Postdoctoral Fellowship (1975-1977) and a NATO Fellowship (1977-1978) before joining the CNRS at Gif-sur-Yvette as Attaché de Recherche. In 1980 he returned to Oxford to take up a University Lectureship in Chemistry. In 1996, he became Professor of Chemistry (Oxford) and in 2006, the Waynflete Professor of Chemistry (Oxford).
Whilst remaining an active academic, Davies founded Oxford Asymmetry Ltd (an asymmetric synthesis company) in 1991 as sole investor. He also founded Oxford Diversity Ltd (a combinatorial chemistry company). These two companies were merged to form Oxford Asymmetry International Plc in 1999 which was sold to Evotec in 2000 for £316m. In 2003 he founded VASTox (Value Added Screening Technology Oxford), a zebrafish screening company. It floated on AIM in 2004 and changed its name to Summit plc in 2007. Summit raised £23m in a follow-on offering in 2014 in order to conduct phase 2 studies of a utrophin modulator, discovered in Davies’ lab, in Duchenne Muscular Dystrophy and an in-licensed small molecule for the treatment of Clostridium difficile. In addition, Davies is founder and editor-in-chief for Tetrahedron: Asymmetry.
James MallinsonNon-Executive Director
James Mallinson has over 25 years' experience in venture capital. He has made investments in, and been closely involved with the development of, many technology companies including: NaturalMotion, acquired by Zynga Inc for over $527m in February 2014; Oxford Immunotec, which raised $64m on the NASDAQ stock exchange in November 2013; Yasa Motors, a privately held company developing class leading very high power to weight ratio electric motors; Adaptimmune, floated on NASDAQ in May 2015 raising $171m; Crysalin, which is developing new techniques for protein structure determination, and many others. James is a partner at Oxford Investment Consultants (OIC). Prior to this he was Director of Spin-out Equity Management at Oxford University Innovation. James is an Engineering Science graduate from the University of Oxford and gained his MBA from Cranfield University in 1990.
Bob DugganNon-Executive Director
Bob Duggan is an experienced entrepreneur with multiple successful companies to his name. His first, Sunset Designs, gave a $15m return on a $100k investment. In 1976 he founded Paradise Bakery, which became a market leader in the American freshly baked food industry. Bob moved into the field of technology in the mid 1980s and was a crucial driver of success for the company ‘Government Technology Services’, orchestrating their IPO. Bob has accumulated wealth of experience on a variety of Board of Directors since then and has delivered a series of notable successes to many other companies in the fields of technology, media and biotechnology. Of particular note is his recent resounding success with Pharmacyclics – a biotechnology company that was sold to AbbVie for $21 billion in May 2015 and of which Bob was the Chief Executive Officer.
Simon Read Ph.DEntrepreneur-in-Residence, Atlas
Simon is Entrepreneur-in-Residence at Atlas Ventures, Boston, US. Prior to joining Atlas, Simon was CSO at Ra Pharma (NASDAQ: RARX) until its acquisition by UCB Pharma in 1Q 2020. Simon brings to Oxstem more than 25 years of R&D experience including leadership roles at GlaxoSmithKline, AstraZeneca and Roche/Genentech. Simon has worked on the clinical development of some of the most well-known drugs in the immunology area, including Rituxan® and Actemra®. Simon is a member of the Technology Development Fund for Boston Children’s Hospital, an innovation fund focused on diseases of children, a Fellow of the Royal Society of Medicine and is well published, having authored over 50 articles in peer reviewed journals.